Peroxisome proliferator activated receptor γ protein expression is asymmetrically distributed in primary lung tumor and metastatic to lung osteosarcoma samples and does not correlate with gene methylation

BMC Veterinary Research

Jeffrey N. Bryan³  Senthil R. Kumar³  Dae Young Kim¹  Chamisa L. Herrera² 

[1] Veterinary Medical Diagnostic Laboratory, College of Veterinary Medicine, University of Missouri, Columbia MO 65211, USA;Current Address: BluePearl Seattle, 11536 Lake City Way NE, Seattle WA 98125, USA;Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia MO 65211, USA

关键词: Rosiglitazone;    Lung cancer;    DNA Methylation;    Epigenetics;    Peroxisome proliferator activated receptor-γ (PPAR-γ);   

Others  :  1224244
DOI  :  10.1186/s12917-015-0547-x

 received in 2015-04-30, accepted in 2015-08-21,  发布年份 2015

【 摘 要 】

Background

Peroxisome proliferator activated receptor-γ (PPAR-γ) is a ligand-dependent transcription factor that plays important roles in cellular proliferation and differentiation. It has been implicated as a tumor suppressor in many solid tumors including human prostate, breast, colon, and lung cancer. The objective of this study was to determine the tissue distribution of PPAR-γ in normal canine lung, canine lung cancer, and metastatic to lung cancer, as well as determine the role, if any, of DNA methylation in epigenetic control of gene expression. The protein was studied using immunohistochemistry (IHC) and DNA methylation was studied using combined bisulfite restriction analysis (COBRA), and methylation-specific PCR (MSP).

Results

PPAR-γ is expressed in all large conducting airways, particularly in goblet cells and bronchial glands, in the canine lung. The protein is also expressed in interstitial macrophages. PPAR-γ is expressed in 33 % of canine non-small cell lung cancer (NSCLC) cases and 66 % of metastatic osteosarcoma (OSA) cases. There is a significant loss of 5′ PPAR-γ methylation from normal lung to primary lung cancer and metastatic OSA (p = 0.0002), however altered PPAR-γ promoter methylation at the interrogated locus does not appear to be associated with changes in protein expression.

Conclusions

PPAR-γ protein is expressed in normal canine lung tissue, canine primary lung cancer, and metastatic OSA. Confirmation of PPAR-γ protein expression in tumor-bearing dogs supports the investigation of PPAR-γ agonists in this subset of veterinary patients. These results are the first to describe epigenetic marks and protein localization of PPAR-γ among different lung pathologies in the dog.

【 授权许可】

   
2015 Herrera et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

【 参考文献 】

• [1]Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc Natl Acad Sci. 1997; 94:4318-4323.
• [2]Chinetti G, Fruchart J-C, Staels B. Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res. 2000; 49:497-505.
• [3]Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 1998; 391:79-82.
• [4]Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 2004; 5:419-429.
• [5]Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer. 2012; 12:181-195.
• [6]Han SW, Roman J. Activated PPARgamma targets surface and intracellular signals that inhibit the proliferation of lung carcinoma cells. PPAR Res. 2008; 2008:254108.
• [7]Keshamouni VG, Reddy RC, Arenberg DA, Joel B, Thannickal VJ, Kalemkerian GP, Standiford TJ. Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer. Oncogene. 2004; 23:100-108.
• [8]Li H, Weiser-Evans MCM, Nemenoff R. Anti- and protumorigenic effects of PPARγ; in lung cancer progression: a double-edged sword. PPAR Res. 2012;2012.
• [9]Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60:277-300.
• [10]Chang T-H, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer. Cancer Res. 2000; 60:1129-1138.
• [11]Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, Inoue K, Hla T, Kondo M. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis. Biochem Biophys Res Commun. 2000; 270:400-405.
• [12]Rowell JL, McCarthy DO, Alvarez CE. Dog models of naturally occurring cancer. Trends Mol Med. 2011; 17:380-388.
• [13]Breen M, Modiano JF. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans – man and his best friend share more than companionship. Chromosome Res. 2008; 16:145-154.
• [14]Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer. 2008; 8:147-156.
• [15]Kraegel SA, Gumerlock PH, Dungworth DL, Oreffo VIC, Madewell BR. K-ras activation in Non-small cell lung cancer in the dog. Cancer Res. 1992; 52:4724-4727.
• [16]Hifumi T, Miyoshi N, Kawaguchi H, Nomura K, Yasuda N. Immunohistochemical detection of proteins associated with multidrug resistance to anti-cancer drugs in canine and feline primary pulmonary carcinoma. J Vet Med Sci Jpn Soc Vet Sci. 2010; 72:665-668.
• [17]Khanna C, Vail DM. Targeting the lung: preclinical and comparative evaluation of anticancer aerosols in dogs with naturally occurring cancers. Curr Cancer Drug Targets. 2003; 3:265-273.
• [18]Hershey IDK AE. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin Cancer Res Off J Am Assoc Cancer Res. 1999; 5:2653-9.
• [19]Sozmen M, Kabak YB, Gulbahar MY, Gacar A, Karayigit MO, Guvenc T, Yarim M. Immunohistochemical characterization of peroxisome proliferator-activated receptors in canine normal testis and testicular tumours. J Comp Pathol. 2013; 149:10-18.
• [20]Paciello O, Borzacchiello G, Varricchio E, Papparella S. Expression of peroxisome proliferator-activated receptor gamma (PPAR-γ) in canine nasal carcinomas. J Vet Med Ser A. 2007; 54:406-410.
• [21]Toseland CDN, Campbell S, Francis I, Bugelski PJ, Mehdi N. Comparison of adipose tissue changes following administration of rosiglitazone in the dog and rat. Diabetes Obes Metab. 2001; 3:163-170.
• [22]Frazier SA, McKemie DS, Guerrero TA, Skorupski KA, Rodriguez CO. Evaluation of an extractionless high-performance liquid chromatography-tandem mass spectrometry method for detection and quantitation of rosiglitazone in canine plasma. Am J Vet Res. 2011; 72:263-270.
• [23]Allstadt Frazier S, McKemie DS, Guerrero TA, LaChapelle H, Skorupski KA, Kass PH, Rodriguez CO. Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer-bearing dogs. Vet Comp Oncol. 2014; 12:1-9.
• [24]Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012; 13:484-492.
• [25]Braissant O, Foufelle F, Scotto C, Dauça M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 1996; 137:354-366.
• [26]Simon DM, Arikan MC, Srisuma S, Bhattacharya S, Tsai LW, Ingenito EP, Gonzalez F, Shapiro SD, Mariani TJ. Epithelial cell PPARγ contributes to normal lung maturation. FASEB J. 2006; 20:1507-1509.
• [27]Liu D, Xiong Zeng B, Shang Y. Decreased expression of peroxisome proliferator-activated receptor γ in endotoxin-induced acute lung injury. Physiol Res. 2006; 55:291-299.
• [28]Ameshima S, Golpon H, Cool CD, Chan D, Vandivier RW, Gardai SJ, Wick M, Nemenoff RA, Geraci MW, Voelkel NF. Peroxisome proliferator-activated receptor gamma (PPARγ) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res. 2003; 92:1162-1169.
• [29]Theocharis S, Kanelli H, Politi E, Margeli A, Karkandaris C, Philippides T, Koutselinis A. Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade. Lung Cancer. 2002; 36:249-255.
• [30]Giaginis C, Politi E, Alexandrou P, Sfiniadakis J, Kouraklis G, Theocharis S. Expression of peroxisome proliferator activated receptor-gamma (PPAR-γ) in human non-small cell lung carcinoma: correlation with clinicopathological parameters, proliferation and apoptosis related molecules and patients’ survival. Pathol Oncol Res. 2012; 18:875-883.
• [31]Mukunyadzi P, Ai L, Portilla D, Barnes EL, Fan C-Y. Expression of peroxisome proliferator-activated receptor gamma in salivary duct carcinoma: immunohistochemical analysis of 15 cases. Mod Pathol. 2003; 16:1218-1223.
• [32]Zhang GY, Ahmed N, Riley C, Oliva K, Barker G, Quinn MA, Rice GE. Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. Br J Cancer. 2004; 92:113-119.
• [33]Shibuya A, Wada K, Nakajima A, Saeki M, Katayama K, Mayumi T, Kadowaki T, Niwa H, Kamisaki Y. Nitration of PPARgamma inhibits ligand-dependent translocation into the nucleus in a macrophage-like cell line, RAW 264. FEBS Lett. 2002; 525:43-47.
• [34]Haydon RC, Zhou L, Feng T, Breyer B, Cheng H, Jiang W, Ishikawa A, Peabody T, Montag A, Simon MA, He T-C. Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin Cancer Res. 2002; 8:1288-1294.
• [35]Haydon RC, Luu HH, He T-C. Osteosarcoma and osteoblastic differentiation: a new perspective on oncogenesis. Clin Orthop. 2007; 454:237-246.
• [36]Tang N, Song W-X, Luo J, Haydon RC, He T-C. Osteosarcoma development and stem cell differentiation. Clin Orthop. 2008; 466:2114-2130.
• [37]Wagner ER, He B-C, Chen L, Zuo G-W, Zhang W, Shi Q, et al. Therapeutic Implications of PPARγ in Human Osteosarcoma. PPAR Res 2010, 2010. doi: 10.1155/2010/956427
• [38]Fuke C, Shimabukuro M, Petronis A, Sugimoto J, Oda T, Miura K, Miyazaki T, Ogura C, Okazaki Y, Jinno Y. Age related changes in 5-methylcytosine content in human peripheral leukocytes and placentas: an HPLC-based study. Ann Hum Genet. 2004; 68:196-204.
• [39]Ru G, Terracini B, Glickman LT. Host related risk factors for canine osteosarcoma. Vet J. 1998; 156:31-39.
• [40]Withrow SJ, Vail DM, Page RL. Withrow and MacEwen’s small animal clinical oncology. Elsevier Health Sciences, London; 2013.
• [41]Griffey SM, Kraegel SA, Madewell BR. Rapid detection of K-ras gene mutations in canine lung cancer using single-strand conformational polymorphism analysis. Carcinogenesis. 1998; 19:959-963.
• [42]Ogilvie GK, Haschek WM, Withrow SJ, Richardson RC, Harvey HJ, Henderson RA, Fowler JD, Norris AM, Tomlinson J, McCaw D. Classification of primary lung tumors in dogs: 210 cases (1975–1985). J Am Vet Med Assoc. 1989; 195:106-108.
• [43]Polton GA, Brearley MJ, Powell SM, Burton CA. Impact of primary tumour stage on survival in dogs with solitary lung tumours. J Small Anim Pract. 2008; 49:66-71.
• [44]Boston SE, Ehrhart NP, Dernell WS, Lafferty M, Withrow SJ. Evaluation of survival time in dogs with stage III osteosarcoma that undergo treatment: 90 cases (1985–2004). J Am Vet Med Assoc. 2006; 228:1905-1908.
• [45]Boileau C, Martel-Pelletier J, Fahmi H, Mineau F, Boily M, Pelletier J-P. The peroxisome proliferator–activated receptor γ agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: In vivo protective effects mediated through the inhibition of key signaling and catabolic pathways. Arthritis Rheum. 2007; 56:2288-2298.
• [46]Nemoto S, Razeghi P, Ishiyama M, Freitas GD, Taegtmeyer H, Carabello BA. PPAR-γ agonist rosiglitazone ameliorates ventricular dysfunction in experimental chronic mitral regurgitation. Am J Physiol - Heart Circ Physiol. 2005; 288:H77-H82.
• [47]Li L-C, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinforma Oxf Engl. 2002; 18:1427-1431.
• [48]Kowalewski MP, Meyer A, Hoffmann B, Aslan S, Boos A. Expression and functional implications of Peroxisome Proliferator—Activated Receptor Gamma (PPARγ) in canine reproductive tissues during normal pregnancy and parturition and at antiprogestin induced abortion. Theriogenology. 2011; 75:877-886.